Abliva, a Swedish pharmaceutical company who develop medicines for the treatment of mitochondrial diseases, announced this week that interim analysis of their FALCON study has been positive, with independent body the Data Monitoring Committee recommending that the study continue without any modification.
The study is investigating whether the company’s newly developed drug, KL1333, can improve the symptoms of chronic fatigue and myopathy (muscle weakness) in adult patients living with a genetic diagnosis of mitochondrial disease.
The Lily Foundation’s Research Manager Maria commented on the news: “Clinical research studies like this one are crucial in the path to discovering treatments for mitochondrial disease, so we’re encouraged to hear this positive step. We know a number of patients from within our mito community are part of this study at sites in Cambridge, UCL and Newcastle, and having supported the initial recruitment to the trial, we’re pleased to hear of its progress.”
We wish the Abliva team continued success with the study and look forward to future updates.
Read Abliva’s press release.